The FDA this week released a warning letter it sent to Becton Dickinson (NYSE: BDX) last month over issues it found at the company’s Franklin, Wisc.-based facilities, which produces pre-filled Heparin and 0.9% sodium chloride lock flush syringes.
The warning letter came from an inspection of the facilities which took place between May 16, 2018 and August 1, 2018, and includes a response from BD that the federal watchdog received on August 21 this year.
Read the whole story on our sister site, Drug Delivery Business News
The post FDA releases BD lock flush syringe facility warning letter appeared first on MassDevice.
from MassDevice https://ift.tt/2IPourN
Cap comentari:
Publica un comentari a l'entrada